ROCKET PHARMACEUTICALS, INC. 8-K

What Happened

• On February 26, 2026, Rocket Pharmaceuticals, Inc. (RCKT) announced certain financial information for the quarter and fiscal year ended December 31, 2025 and furnished a related press release. The company reported this information via a Current Report on Form 8‑K (Item 2.02) and included the press release as Exhibit 99.1.

Key Details

• Filing date: February 26, 2026 (Form 8‑K, Items 2.02 and 9.01).
• Reporting period: quarter and fiscal year ended December 31, 2025.
• Disclosure format: press release furnished as Exhibit 99.1; Cover Page Interactive Data File (Inline XBRL) furnished as Exhibit 104.
• The 8‑K furnishes the financial information (the press release) rather than amending prior financial statements.

Why It Matters

• This filing signals Rocket has updated investors on its recent earnings/financial condition for Q4 and full year 2025. The press release will contain the specific revenue, expense, cash position and other quarterly results investors use to assess company performance.
• Retail investors should read Exhibit 99.1 (the press release) and the company’s full filings for the detailed numbers and management commentary, as those items can affect valuation, near-term financing needs, and development program progress.